» Articles » PMID: 24786912

Drug-induced Peripheral Neuropathy

Overview
Specialties Pharmacology
Toxicology
Date 2014 May 3
PMID 24786912
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Peripheral neuropathy can be caused by medication, and various descriptions have been applied for this condition. In this MiniReview, the term 'drug-induced peripheral neuropathy' (DIPN) is used with the suggested definition: Damage to nerves of the peripheral nervous system caused by a chemical substance used in the treatment, cure, prevention or diagnosis of a disease. Optic neuropathy is included in this definition. A distinction between DIPN and other aetiologies of peripheral neuropathy is often quite difficult and thus, the aim of this MiniReview is to discuss the major agents associated with DIPN.

Citing Articles

Effect of Multicomponent Exercise Program on Pain and Functional Mobility in Antitubercular Drug Therapy-Induced Peripheral Neuropathy in Pulmonary Tuberculosis Survivors.

Hiwalkar T, Shinde S, Dhumale A Cureus. 2024; 16(7):e65431.

PMID: 39184691 PMC: 11344632. DOI: 10.7759/cureus.65431.


Evaluation of the Effect of Loratadine versus Diosmin/Hesperidin Combination on Vinca Alkaloids-Induced Neuropathy: A Randomized Controlled Clinical Trial.

Kamal N, Abdallah M, Abdel Wahed E, Sabri N, Fahmy S Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794179 PMC: 11124025. DOI: 10.3390/ph17050609.


Frostbite secondary to antimycobacterial-induced peripheral neuropathy: a case report.

Alanazi S, Bali D, Alwagdani N, Mal Y, Alkhatieb M, AlJaaly H Int J Burns Trauma. 2024; 14(2):32-37.

PMID: 38764892 PMC: 11101997. DOI: 10.62347/GHPO4831.


Antibiotics and Lipid-Modifying Agents: Potential Drug-Drug Interactions and Their Clinical Implications.

Spanakis M, Alon-Ellenbogen D, Ioannou P, Spernovasilis N Pharmacy (Basel). 2023; 11(4).

PMID: 37624085 PMC: 10457919. DOI: 10.3390/pharmacy11040130.


Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study.

Djochie R, Anto B, Opare-Addo M J Pharm Policy Pract. 2023; 16(1):70.

PMID: 37291618 PMC: 10249546. DOI: 10.1186/s40545-023-00577-6.